Cyclosporine C2 Target Levels and Acute Cellular Rejection After Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 25, Issue 8, 2006, Pages 928-934

  Glanville, Allan R ^a   Aboyoun, Christina L ^a   Morton, Judith M ^b   Plit, Marshall ^a   Malouf, Monique A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GANCICLOVIR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RIFAMPICIN; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HIRSUTISM; HUMAN; KIDNEY DYSFUNCTION; LUNG GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MONITORING; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TRANSBRONCHIAL BIOPSY; VIRUS PNEUMONIA;

ACUTE DISEASE; ADOLESCENT; ADULT; BRONCHIOLITIS OBLITERANS; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 33746548417     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.03.020     Document Type: Article

References (46)

1. Andert S.E., Grimm M., Schreiner W., and Muller M.M. Therapeutic whole-blood levels of cyclosporin A in heart and lung transplantation. Clin Chim Acta 224 (1994) 159-166
2. David-Neto E., Araujo L.M., Brito Z.M., et al. Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am J Transplant 2 (2002) 546-550
3. Jorga A., Johnston A., and Holt D.W. Patient management by cyclosporine C2 monitoring. Transplantation 77 (2004) 323-324
4. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Anonymous. Am J Transplant 2 (2002) 148-156
5. Estenne M., Maurer J.R., Boehler A., et al. Bronchiolitis obliterans syndrome 2001. an update of the diagnostic criteria. J Heart Lung Transplant 21 (2002) 297-310
6. Hopkins P.M., Aboyoun C.L., Chhajed P.N., et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 170 (2004) 1022-1026
7. Levy G., Burra P., Cavallari A., et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 73 (2002) 953-959
8. Chou N.K., Chen R.J., Ko W.J., et al. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan. Transplant Proc 36 (2004) 2393-2395
9. Di Paolo S., Teutonico A., Schena A., et al. Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients. results at 3 years. Am J Kidney Dis 44 (2004) 886-892
10. Nashan B., Bock A., Bosmans J.L., et al. Use of Neoral C2 monitoring. a European consensus. Transplant Int 18 (2005) 768-778
11. Jaksch P., Kocher A., Neuhauser P., et al. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). J Heart Lung Transplant 24 (2005) 1076-1080
12. Knoop C., Vervier I., Thiry P., et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation. comparison between cystic fibrosis and other conditions. Transplantation 76 (2003) 683-688
13. Glanville A.R., Morton J.M., Aboyoun C.L., Plit M.L., and Malouf M.A. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation. J Heart Lung Transplant 23 (2004) 1170-1174
14. Fisher N.C. Renal failure after lung transplantation. Lancet 352 (1998) 69-70
15. Cole E., Maham N., Cardella C., et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 75 (2003) 2086-2090
16. Pattison J.M., Petersen J., Kuo P., Valantine V., Robbins R.C., and Theodore J. The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 26 (1995) 643-648
17. Zaltzman J.S., Pei Y., Maurer J., Patterson A., and Cattran D.C. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 54 (1992) 875-878
18. Morton J.M., Aboyoun C.L., Malouf M.A., Plit M.L., and Glanville A.R. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 23 (2004) 1035-1039
19. Glanville A.R., and Estenne M. Indications, patient selection and timing of referral for lung transplantation. Eur Respir J 22 (2003) 845-852
20. Maurer J.R., Frost A.E., Estenne M., Higenbottam T., Glanville A.R., The International Society for Heart and Lung Transplantation, American Thoracic Society, American Society of Transplant Physicians, and European Respiratory Society. International guidelines for the selection of lung transplant candidates. Transplantation 66 (1998) 951-956
21. Levy G., Thervet E., Lake J., and Uchida K. Patient management by Neoral C(2) monitoring. an international consensus statement. Transplantation 73 suppl (2002) S12-S18
22. Levy G., Villamil F., Samuel D., et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77 (2004) 1632-1638
23. Morris R.G., Russ G.R., Cervelli M.J., et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 24 (2002) 479-486
24. Morales J., Buckel E., Fierro A., et al. A simple method to calculate cyclosporine dosage to obtain a target C2 drug level. Ther Drug Monit 25 (2003) 389-392
25. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection. Lung Rejection Study Group. J Heart Lung Transplant 15 (1996) 1-15
26. Tamm M., Aboyoun C.L., Chhajed P.N., et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 170 (2004) 1120-1123
27. Aboyoun C.L., Tamm M., Chhajed P.N., et al. Diagnostic value of follow-up transbronchial lung biopsy after lung rejection. Am J Respir Crit Care Med 164 (2001) 460-463
28. Hopkins P.M., Aboyoun C.L., Chhajed P.N., et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 21 (2002) 1062-1067
29. Standardization of spirometry-1987 update. Statement of the American Thoracic Society. Anonymous. Am Rev Respir Dis 136 (1987) 1285-1298
30. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation. twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 (2005) 956-967
31. McNeil K., Glanville A.R., Wahlers T., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 81 (2006) 998-1003
32. Moffatt S.D., Demers P., Robbins R.C., et al. Lung transplantation. a decade of experience. J Heart Lung Transplant 24 (2005) 145-151
33. Meyers B.F., Lynch J., Trulock E.P., et al. Lung transplantation. a decade of experience. Ann Surg 230 (1999) 362-370
34. Harringer W., Wiebe K., Struber M., et al. Lung transplantation-10-year experience. Eur J Cardiothorac Surg 16 (1999) 546-554
35. Smeritschnig B., Jaksch P., Kocher A., et al. Quality of life after lung transplantation. a cross-sectional study. J Heart Lung Transplant 24 (2005) 474-480
36. Thabut G., Mal H., Cerrina J., et al. Graft ischemic time and outcome of lung transplantation. a multicenter analysis. Am J Respir Crit Care Med 171 (2005) 786-791
37. Glanville A.R., Scott A.I., Morton J.M., et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 24 (2005) 2114-2119
38. Glanville A.R., Gencay M., Tamm M., et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 24 (2005) 131-136
39. O'Halloran E.K., Reynolds J.D., Lau C.L., et al. Laparoscopic Nissen fundoplication for treating reflux in lung transplant recipients. J Gastrointest Surg 8 (2004) 132-137
40. Villamil F., and Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients. the clinician's perspective. Liver Transplant 10 (2004) 577-583
41. Best N.G., Tan K.K., Trull A.K., et al. Pharmacodynamics of cyclosporine in heart and heart-lung transplant recipients. II: Blood cyclosporine concentrations and other risk factors for lung allograft rejection. Transplantation 62 (1996) 1436-1441
42. Felipe C.R., Silva Jr. H.T., Machado P.G., et al. Time-dependent changes in cyclosporine exposure. implications for achieving target concentrations. Transplant Int 16 (2003) 494-503
43. Hamwi A., Salomon A., Steinbrugger R., et al. Cyclosporine metabolism in patients after kidney, bone marrow, heart-lung, and liver transplantation in the early and late posttransplant periods. Am J Clin Pathol 114 (2000) 536-543
44. Akhlaghi F., Gonzalez L., and Trull A.K. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. J Heart Lung Transplant 24 (2005) 2120-2128
45. Johnston A., Chusney G., Schutz E., et al. Monitoring cyclosporin in blood. between-assay differences at trough and 2 hours post-dose (C2). Ther Drug Monit 25 (2003) 167-173
46. Gunes A., Aboyoun C.L., Morton J.M., et al. Lung transplantation for chronic obstructive pulmonary disease at St Vincent's Hospital. Intern Med J 36 (2006) 5-11